Procyte About Us Copper Peptide Technology Products By Category Products By Brand Physicians' Links Investor Relations
     
 












Market Data
                  Investment Profiles
Stock Exchange: OTCBB                  
Daily Trends.com Small Cap Pick of the Week
SM Berger ProCyte Investment Profile
The Acker Letter
 
Ticker Symbol: PRCY                   You'll need Adobe Acrobat Reader™ to view these PDF files. If you don't have it or you want to upgrade to the new version 4.0, click on the Adobe Acrobat icon below.

Transfer Agent
Computershare Investor Services
350 Indiana Street
Golden, CO 80401
(303) 262-0709
Industry: Biotechnology                  
52 Week Price Range                  
High: $1.74                  
Low: $0.88                  
Shares Outstanding: 15.8 Million                  
Public Float: 15.1 Million                  

*Information may be delayed for up to one hour.

Forward Looking Statements

This site may contain forward-looking statements relating to the research, development, commercialization, production, marketing and distribution of the Company's products and future operating results that are subject to certain risks and uncertainties which could cause actual results to differ materially from those projected. The words “believe,” “expect,” “intend,” “anticipate,” variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. [Factors that could affect the Company’s actual results include its ability to develop, commercialize and produce new products, the market acceptance of existing and potential future products, the availability, cost and timely delivery of materials and services from and performance of third party suppliers, manufacturers, distributors, licensees and other collaborative partners, the satisfaction of regulatory requirements, and the receipt, timing, terms and conditions of required regulatory approvals.] Reference is made to the Company’s latest Quarterly Report on Form 10Q or Form 10K filed with the Securities and Exchange Commission for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.
 
Copyright © 2000-2004 Procyte Corporation. All Rights Reserved. Contact Us    Site Map